Advertisement

U.K. approves Merck antiviral pill to treat COVID-19

Click to play video: 'Infectious disease physician responds after Merck antiviral pill approved for use in the UK' Infectious disease physician responds after Merck antiviral pill approved for use in the UK
WATCH: The world’s first antiviral pill for treating COVID-19 has been approved in the United Kingdom. Merck says Molnupiravir reduces COVID-19 symptoms and speeds up recovery. Infectious diseases physician Dr. Andrew Morris spoke with Global News about the pill and how it works – Nov 4, 2021

Britain on Thursday became the first country in the world to approve a potentially game-changing COVID-19 antiviral pill jointly developed by U.S.-based Merck and Ridgeback Biotherapeutics, in a boost to the fight against the pandemic.

Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) recommended the drug, molnupiravir, be used as soon as possible following a positive COVID-19 test and within five days of the onset of symptoms, citing clinical data.

Read more: Experimental pill fights COVID-19, drug-maker Merck claims

Click to play video: 'Health Canada considers Merck’s experimental COVID-19 drug' Health Canada considers Merck’s experimental COVID-19 drug
Health Canada considers Merck’s experimental COVID-19 drug – Oct 4, 2021

This is the first oral antiviral treatment for COVID-19 to get approved, with the green light coming ahead of potential U.S. regulatory clearance. U.S. advisers will meet this month to vote on whether molnupiravir should be authorized.

Story continues below advertisement

Treatments to tackle the pandemic, which has killed more than 5.2 million people worldwide, have so far focused mainly on vaccines. Other options, including Gilead’s infused antiviral remdesivir and generic steroid dexamethasone, are generally only given after a patient has been hospitalized.

Click to play video: 'Fauci says Merck data on its COVID-19 pill treatment ‘impressive’' Fauci says Merck data on its COVID-19 pill treatment ‘impressive’
Fauci says Merck data on its COVID-19 pill treatment ‘impressive’ – Oct 1, 2021

Merck’s molnupiravir has been closely watched since data last month showed it could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19 when given early in the illness.

The drug, to be branded Lagevrio in Britain, is designed to introduce errors into the genetic code of the virus that causes COVID-19 and is taken twice a day for five days.

The British government and the country’s National Health Service (NHS) will confirm how the treatment will be deployed to patients in “due course.”

Story continues below advertisement

“We are working at pace across the government and with the NHS to set out plans to deploy molnupiravir to patients through a national study as soon as possible,” health secretary Sajid Javid said in a statement.

The speedy approval in Britain comes as the government struggles to tame soaring infections.

Read more: Regeneron’s antibody COVID-19 treatment is popular in the U.S. — why not in Canada?

The country has about 40,000 daily cases of COVID-19, according to the latest seven-day average. That total is second only to the roughly 74,000 a day in the United States, which has five times more people.

Data released on Wednesday night showed COVID-19 prevalence in England hit its highest level on record last month, led by a high numbers of cases in children and a surge in the south-west of the country.

Pressure is growing on the government to implement its “Plan B” aimed at protecting the NHS from unsustainable demands, involving mask mandates, vaccine passes and work-from-home orders.

Last month, Britain agreed a deal with Merck to secure 480,000 courses of molnupiravir.

Treatment race

In a separate statement, Merck said it was expecting to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022.

Story continues below advertisement

The U.S. based drugmaker’s shares were up 2.1% at $90.54 before the market open.

Pfizer and Roche are also racing to develop easy-to-administer antiviral pills for COVID-19. Pfizer last month began a large study of its oral antiviral drug for the prevention of COVID-19 in people exposed to the coronavirus.

Merck’s molnupiravir is also being studied in a late-stage trial for preventing infection.

Read more: Cheap antidepressant could help treat COVID-19, study finds

Viral sequencing done so far has shown molnupiravir is effective against all variants of the coronavirus, Merck has said, including the more-infectious Delta, which is responsible for the worldwide surge in hospitalizations and deaths recently.

While it is not yet clear when Merck will deliver doses to Britain, the company has said it is committed to providing timely access to its drug globally with plans for tiered pricing aligned with a country’s ability to pay.

Merck is also in talks with generic drugmakers about expanding manufacturing licenses to build supply of the treatment.

Antibody cocktails like those from Regeneron and Eli Lilly have also been approved for non-hospitalized COVID-19 patients, but have to be given intravenously.

Sponsored content